The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD - Boston, MA, USA

Video navigation menu

Residual risk despite agressive LDL-c lowering 01:07
Residual risk: targeting obesity and novel antidiabetes agents 02:31
Residual risk: further reduction of LDL-c and targeting inflammation 05:08
Residual risk: targeting triglycerides and Lp(a) 07:09

Educational information

This video was recorded as part of the two-day meeting 'Current Challenges in Lipid Management and Cardiovascular Risk Reduction' at Brigham and Women's Hospital/Harvard Medical School in Boston, MA, USA on October 31 2019.

Faculty

Erin Bohula, MD is cardiologist at the Brigham and Women's Hospital and investigator of the TIMI study group in Boston, MA, USA.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.